GSK5471713: An Investigational AR Degrader Targeting Late-Stage Prostate Cancer Resistance

/in , , , /by

Note: This article treats GSK5471713 as an androgen receptor (AR) degrader based on GSK’s official clinical trial registry classification and inclusion/exclusion criteria. While confident in the AR degrader designation from the sponsor’s documentation, the specific degradation mechanism (PROTAC, SARD, or other platform) remains undisclosed in publicly available sources at the moment. GSK5471713 is an investigational […]

Read more

BrUOG360 Phase Ib/II Trial: Copanlisib Plus Rucaparib for mCRPC With HRD

/in , , , /by

Copanlisib combined with rucaparib demonstrates tolerability and early signals of activity in metastatic castration-resistant prostate cancer (mCRPC), according to results from the BrUOG360 phase Ib/II trial published in late 2025. ​Metastatic castration-resistant prostate cancer with homologous recombination deficiency (HRD) responds to PARP inhibitors like rucaparib, but many patients develop resistance through alternative DNA repair pathways. […]

Read more

Phase 1 Trial of Allogeneic CAR-NK Therapy for Metastatic Prostate Cancer

/in , , /by

A new clinical trial is exploring allogeneic CAR-NK cell therapy targeting PSMA for patients with metastatic castration-resistant prostate cancer, or mCRPC. This exploratory study (not yet recruiting as of late 2025), aims to assess the safety profile alongside early signs of efficacy in men whose disease has progressed despite hormone suppression and other therapies. Unlike […]

Read more

GVV858: A New Approach to Castration-Resistant Prostate Cancer Phase 1/2 Trial

/in , , , /by

GVV858 is a CDK2 inhibitor designed to block this escape route. Instead of adding another hormone therapy when resistance develops, it targets the cell cycle machinery that CCNE1-amplified tumors depend on. The drug works on the molecular brakes that control when cells divide, rather than trying to manipulate hormone levels further. CCNE1 amplification allows cancer […]

Read more

UPDATE: AB-3028 Reaches Clinical Trial Stage for mCRPC

/in , , , /by

AB-3028, programmable circuit T cell therapy for metastatic castration-resistant prostate cancer (mCRPC), has now advanced into a Phase 1/2 clinical trial. This marks the first clinical testing of this highly engineered, logic‑gated CAR-T platform in prostate cancer, moving it from a purely preclinical concept into human evaluation. The trial should start recruiting in January 2026. […]

Read more

UPDATE: AO-252, a New First-in-Class Brain-Penetrating TACC3 Inhibitor for Prostate Cancer

/in , , /by

A new drug called AO-252, an oral inhibitor of TACC3, is now in phase 1 trials specifically testing it against prostate cancer among other solid tumors. It smartly blocks TACC3’s key partnerships with proteins like KIFC1, clathrin, BRCA1, and others, triggering mitotic disasters and halting growth in both lab models and early patients (some saw tumors […]

Read more

GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial

/in , , , /by

GSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]

Read more

MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors

/in , , , /by

MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]

Read more

UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2

/in , , , /by

TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]

Read more

Phase 1 Trial for ITC-6146RO, Antibody-Drug Conjugate Targeting B7-H3

/in , , /by

ITC-6146RO is an experimental cancer drug belonging to the class of antibody–drug conjugates, or ADCs. It received IND Approval from Korean Ministry of Food and Drug Safety (Following U.S. FDA) to start a first‑in‑human Phase 1 trial in people with advanced or metastatic solid tumors who no longer respond to standard therapies. It has been […]

Read more